Glutamine transporter SLC1A5 inhibits autophagy-mediated CD276 degradation to promote esophageal cancer progression
SLC1A5 enhances CD276 stability by suppressing ROS-autophagy signaling, promoting ESCC progression. Targeting glutamine metabolism to enhance CD276 degradation might be a novel therapeutic strategy for ESCC.
Authors
- Chaonan Guan (ORCID: https://orcid.org/0000-0001-6542-2229)
- Heng Zhang (ORCID: https://orcid.org/0000-0002-0103-2173)
- Chunyan Wang
- Yuying Li
- Shengli Yang
- Lan Huang
Institutions
- First Affiliated Hospital of Zhengzhou University (CN)
Publication Details
- Journal
- Cancer Biology & Therapy
- Published
- 2026-01-28
- DOI
- https://doi.org/10.1080/15384047.2026.2621606
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00